Correlation of Antifactor Xa Concentrations with Renal Function in Patients on Enoxaparin

Journal of Clinical Pharmacology - Tập 43 Số 6 - Trang 586-590 - 2003
Sheryl L. Chow1, Kimberly Zammit1, Kathleen West1, MaryAnne Dannenhoffer1, Angel López‐Candales1
1From the University at Buffalo, State University of New York, Kaleida Health Systems, Buffalo, New York.

Tóm tắt

Enoxaparin is a low molecular weight heparin (LMWH) that has been shown to be effective in deep vein thrombosis, pulmonary embolism, and unstable angina. Because renal function plays an important role in the clearance of LMWH, the authors sought to investigate the effect of renal function on enoxaparin. This prospective multiple‐dose study evaluated 18 patients with varying degrees of renal function initiated on enoxaparin 1 mg/kg subcutaneously every 12 hours. Peak blood levels of anti‐Xa concentrations were obtained 4 ± 0.5 hours postdose after receiving at least three doses of enoxaparin. The median antifactor Xa levels were higher in patients with creatinine clearance (CLCr) ≤ 30 mL/min compared to CLCr ≥ 31 mL/min (1.34 IU/mL vs. 0.91 IU/mL, respectively, p < 0.05). A linear correlation was established between creatinine clearance and anti‐Xa concentrations (p < 0.0005). On the basis of the data, the authors believe that a dose adjustment is necessary in patients receiving repeated doses of enoxaparin with CLCr ≤ 30 mL/min.

Từ khóa


Tài liệu tham khảo

Eriksson BI, 1991, Prevention of deep‐vein thrombosis and pulmonary embolism after total hip replacement: comparison of low molecular weight heparin and unfractionated heparin, J Bone Joint Surg, 73, 484, 10.2106/00004623-199173040-00002

10.1001/archinte.1993.00410130045005

10.1016/S0140-6736(96)91270-2

Klein W, 1996, Low molecular weight heparin in the initial and prolonged treatment of unstable coronary artery disease: the Fragmin in Unstable Coronary Heart Disease study (FRIC) [abstract], Eur Heart J, 17, 306

10.1056/NEJM199708143370702

Cziraky MJ, 1993, Low molecular weight heparins for the treatment of deep vein thrombosis, Clin Pharm, 12, 892

10.1182/blood.V79.1.1.1

10.1111/j.1365-2141.1995.tb03373.x

10.1378/chest.108.4_Supplement.258S

Boneau B, 1990, Bailliere's Clinical Haematology, Antithrombotic Therapy, 531

10.1016/0049-3848(91)90141-I

10.2165/00003495-199244030-00010

10.7326/0003-4819-130-6-199903160-00002

STACHROM® Heparin Assay [product information] Diagnostica Stago France 1996.

10.1592/phco.21.2.169.34113

10.1016/S0167-5273(01)00455-7

Lovenox® [product information] Aventis Pharmaceuticals Bridgewater NJ 2001.

10.1592/phco.20.9.771.35210

10.1067/mhj.2002.120774

Laposata M, 1998, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy, Arch Path Lab Med, 122, 799